| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Efe, C., et al.
(författare)
-
Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome
- 2021
-
Ingår i: Journal of Gastroenterology and Hepatology. - : Wiley. - 0815-9319 .- 1440-1746. ; 36:4, s. 936-942
-
Tidskriftsartikel (refereegranskat)abstract
- Background and Aim The prevalence and clinical significance of extrahepatic autoimmune diseases (EHAIDs) have not been evaluated in a large cohort of primary biliary cholangitis (PBC). Methods The medical records of 1554 patients with PBC from 20 international centers were retrospectively reviewed. Development of decompensated cirrhosis (ascites, variceal bleeding, and/or hepatic encephalopathy) and hepatocellular carcinoma were considered clinical endpoints. Results A total of 35 different EHAIDs were diagnosed in 440 (28.3%) patients with PBC. Patients with EHAIDs were more often female (92.5%vs86.1%,P < 0.001) and seropositive for anti-mitochondrial antibodies (88%vs84%,P = 0.05) and antinuclear antibodies and/or smooth muscle antibodies (53.8%vs43.6%,P = 0.005). At presentation, patients with EHAIDs had significantly lower levels of alkaline phosphatase (1.76vs1.98 x upper limit of normal [ULN],P = 0.006), aspartate aminotransferase (1.29vs1.50 x ULN,P < 0.001), and total bilirubin (0.53vs0.58 x ULN,P = 0.002). Patients with EHAIDs and without EHAIDs had similar rates of GLOBE high-risk status (12.3%vs16.1%,P = 0.07) and Paris II response (71.4%vs69.4%,P = 0.59). Overall, event-free survival was not different in patients with and without EHAIDs (90.8%vs90.7%,P = 0.53, log rank). Coexistence of each autoimmune thyroid diseases (10.6%), Sjogren disease (8.3%), systemic sclerosis (2.9%), rheumatoid arthritis (2.7%), systemic lupus erythematosus (1.7%), celiac disease (1.7%), psoriasis (1.5%), and inflammatory bowel diseases (1.3%) did not influence the outcome. Conclusions Our study confirms that EHAIDs are frequently diagnosed in patients with PBC. The presence of EHAIDs may influence the clinical phenotype of PBC at presentation but has no impact on PBC outcome.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Byrne, Sean Anthony, et al.
(författare)
-
From Lenses to Living Rooms : A Policy Brief on Eye Tracking in XR Before the Impending Boom
- 2024
-
Ingår i: 2024 IEEE International Conference on Artificial Intelligence and eXtended and Virtual Reality, AIxVR 2024. - 9798350372021 ; , s. 90-96
-
Konferensbidrag (refereegranskat)abstract
- As tech giants such as Apple and Meta invest heavily in Virtual and Augmented Reality (VR/AR) technologies, often collectively termed Extended Reality (XR) devices, a significant societal concern emerges: The use of eye-tracking technology within these devices. Gaze data holds immense value, revealing insights into user attention, health, and cognitive states. This raises substantial concerns over privacy and fairness, with potential risks of targeted ads, unauthorized surveillance, and data re-purposing. As the impact of eye tracking is due to transition from the lab to the broader public, this paper underscores these pivotal issues in a digestible manner to the general audience. To this end, we first outline the eye-tracking data collection process and its potential for user insights. Second, we introduce perspectives from the domain of privacy, emphasizing its significance as a pivotal measure to guard against the improper use of eye-tracking data. Third, we provide a set of guidelines created by researchers actively working within this space. These recommendations are designed to guide policymakers and the general public toward establishing informed, equitable, and privacy-centric standards surrounding these devices.
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
